

ASX Release

## **O<sub>2</sub> Vent Adopted by Regional Sleep Group and largest Dental Group in North Carolina**

### **Key points:**

- **In line with Oventus' strategy of engaging with the sleep community to drive adoption of Oventus Airway Technology, a collaborative model has been implemented through which the largest comprehensive dental group in North Carolina, USA is working together with a major regional sleep group to implement Oventus' Sleep Treatment Platform**
- **This model will be replicated by region in North America over the coming 12-24 months with accelerating sales expected in the 2H CY2019**

Brisbane, Australia 22 May 2019: Oventus Medical Ltd (ASX: OVN) is pleased to announce the launch of key customers in North Carolina, USA.

In line with the Company's strategy of engaging the sleep and dental channels to deliver care to patients, Oventus' North American team is now working with Dr Domingo Rodriguez-Cue, a board certified Sleep Physician and medical director of one of the largest providers of sleep management services in the US. In tandem, Oventus is also working with Lane Dental, the largest comprehensive dental group in North Carolina to implement the Oventus Sleep Treatment Platform as a new treatment modality for OSA in patients in the Carolinas region in the USA.

Dr Rodriguez-Cue of SleepCues, PA, an innovative sleep medicine practice with four locations across North Carolina, which runs around 400 sleep studies per month commented: "Sleep apnea is one of the most dangerous sleep disorders. Patients with this condition effectively stop breathing while asleep because their airways are obstructed."

He continued, "While some patients benefit from conventional treatments like CPAP, we see many who don't. The Oventus O<sub>2</sub> Vent and treatment platform is the biggest advancement in sleep medicine we've seen for many years. The Oventus Airway Technology unique design delivers air to the back of the throat, allowing for breathing through the oral appliance, bypassing nasal resistance and obstruction of the oropharynx.

We are looking forward to working alongside Lane Dental to deliver Oventus devices to those patients who are currently untreated or dealing with insufficient treatment options."

Founder and CEO of Oventus, Dr Chris Hart added: "Oventus has been working with both SleepCues and Lane Dental over the last two months to educate more than 125 dental and sleep team members throughout North Carolina on the benefits of Oventus Airway Technology and how to implement it into clinical practice.

This is the first region where we are launching our airway technology in both the sleep and dental channels simultaneously. The technology is bringing sleep and dental groups closer together as the incorporation of air channel technology requires oversight of both a sleep physician and a dentist."



# BETTER SLEEP, BETTER HEALTH and a BETTER LIFE

Oventus envisions that this model will be replicated by region in North America over the coming 12-24 months.

Investors are invited to view a recent interview where Dr Rodriguez-Cue of SleepCues, PA speaks about how Oventus O2Vent® devices may be a treatment alternative for sleep apneic patients that can't tolerate CPAP therapy, via the following link on the Oventus website: <https://investors.o2vent.com/dr-rodriguez-cue-interview-on-the-o2vent-treatment-alternative/>.

—ENDS—

For further information, please visit our website at [www.o2vent.com](http://www.o2vent.com) or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: 0409 647 496

Jane Lowe, IR Department: M: 0411 117 774 or [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

## About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while maintaining a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O<sub>2</sub>Vent® is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP<sup>2</sup>. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.<sup>3</sup>

<sup>1</sup> Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010*. Canberra, Australia.

<sup>2</sup> Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

<sup>3</sup> Sutherland et al. *Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*